NeuroSense Therapeutics’ Post

Coya Therapeutics, Inc. concludes Phase II #Alzheimer’s therapy trial: Supported by the Gates Foundation - United States and the Alzheimer’s Association, the #randomised, double-blind, placebo-controlled controlled study is being conducted at Houston Methodist Hospital in the US. The study is aimed at assessing the safety, tolerability, and biological activity of LD IL-2 in mild-to-moderate AD patients. https://lnkd.in/gvZYtDks #RegulatoryBody #Regulations #RegulatoryStrategy

In a conversation with Luisa Torres, PhD of Drug Discovery News, Kyverna Therapeutics Chief Medical Officer James Chung discusses the potential of CAR T-cell therapy for multiple sclerosis, gives an update on #KYV101’s clinical progress, and expresses his enthusiasm for the future of autoimmune disease research at Kyverna. Chung also shares how there is an opportunity to use CAR T cells to test the hypothesis about B cell depletion in a more complete way and to see if there could be unprecedented levels of efficacy. #CARTcelltherapy #AutoimmuneDisease #MultipleSclerosis https://lnkd.in/eqTBG8Yw

It is great to see the early results from this cell therapy trial without the use of IL-2, which can be quite toxic. The value of membrane-bound IL-15 is also highlighted in this trial, assisting cell persistence and survival of the lymphocytes in the harsh tumor microenvironment. We are just beginning to unlock the power of cell therapy. A positive update for the industry.

Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, has announced a collaboration with Physiogenex, a leading preclinical Contract Research Organization (CRO) specializing in metabolic diseases. “The combination of Aiosyn’s NephroPath platform and the preclinical models and research capabilities of Physiogenex enables us to provide our biopharma customers with unique and more comprehensive insights to support them in accelerating renal drug development studies,” said Patrick de Boer, CEO of Aiosyn. Through collaboration, both companies hope to unlock new possibilities in Chronic Kidney Disease drug development, driven by the fast and reproducible quantification of whole kidney tissue and lesions in animal models. #digitalpathology #pathologynews #industrynews

BIOS Builders w/ Sekar (Sek) Kathiresan M.D. - Co-Founder & CEO @ Verve Therapeutics Excited to share my conversation with Sekar Kathiresan exploring Verve's innovative approach to cardiovascular care. This discussion, following our exploration of David R. Liu's base editing research, highlights the clinical translation of such groundbreaking technologies. Verve's strategy focuses on a one-time genetic treatment aimed at permanently reducing LDL cholesterol, a pivotal step towards addressing the primary cause of heart disease. I am thankful for Sek's insights, underscoring the scientific community's efforts to transform patient outcomes through precision medicine. This conversation not only complements our series on profiling breakout life sciences startups featuring the world’s leading builders on the cutting edge of life saving innovations but also illuminates the pathways towards a new era in patient care. -- Guest: Sekar (Sek) Kathiresan M.D. - Co-Founder & CEO @ Verve Therapeutics Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Dr. Kathiresan is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. Dr. Kathiresan’s research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. Among his scientific contributions, Dr. Kathiresan has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention. For his research contributions, he has been honored with a Distinguished Scientist Award from the American Heart Association and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus was the primary prevention of myocardial infarction in individuals with a family history of heart attack. Dr. Kathiresan graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute. #HeartDisease #GeneticEditing #PrecisionMedicine #LifeSciences #BIOSBuilders Tune in: https://buff.ly/3Tgsh6d #HeartHealth #Innovation #Biotech

4D Molecular Therapeutics has announced positive interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients with severe disease activity and a high treatment burden #clinicaltrials #wetAMD #treatmentoptions #ophthalmology #eyehealth #positiveresults #phase2 #ophthalmologist #eyetreatment #eyecare #clinicalresearch #clinicalstudies . . . . . 4D Molecular Therapeutics Arshad M. Khanani David Kirn, MD Robert Kim

🚀 𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔 𝒊𝒏 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚! 🚀 Merck (MSD) has achieved FDA approval for 𝐖𝐞𝐥𝐢𝐫𝐞𝐠 (𝐛𝐞𝐥𝐳𝐮𝐭𝐢𝐟𝐚𝐧), a breakthrough in treating 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐫𝐞𝐧𝐚𝐥 𝐜𝐞𝐥𝐥 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 (𝐑𝐂𝐂). This oral drug offers hope to patients unresponsive to PD-1/PD-L1 inhibitors and VEGF-TKI, demonstrating superior results in the LITESPARK-005 trial. 🔬 Welireg, acquired through the Peloton Therapeutics purchase, has shown impressive progression-free survival (PFS) at 12 and 18 months, surpassing Novartis' Afinitor. With an objective response rate (ORR) difference of 22%, Welireg stands out as a game-changer in RCC treatment. 📊 While interim results raised questions about overall survival (OS) at ESMO Congress, a final analysis is underway. Nonetheless, this HIF-2α inhibitor marks a significant stride in targeting tumor development in kidney cells. 🌐 Renal cell carcinoma affects 81,800 adults in the US annually. Welireg, despite its potential risks, introduces a vital treatment avenue, reducing the risk of disease progression or death compared to everolimus. 👩⚕️ Dr. Toni Choueiri, LITESPARK-005 study chair, emphasizes the significance: "Belzutifan introduces a meaningful new treatment option for certain patients, addressing the gap in options for those progressing post PD-1/PD-L1 and TKI therapy." --------------------------------------------------------------------------------- 🤔What are your views on this FDA Approved ? --------------------------------------------------------------------------------- #fdaapproval #oncology #oncologytrials #carcinoma #marketresearcher #competitiveintelligence #clinicaltrial

There may be a true breakthrough coming in autoimmune, and we will know later this year: our lead Nck modulator AX-158 will be delivering a first patient data readout in psoriasis in Q4. This first-in-class candidate could become a first universal oral therapy for a wide range of autoimmune diseases, if the patient clinical and biomarker data are in line with our comprehensive preclinical and clinical package thus far. At Artax Biopharma, we possess a unique understanding of the role of Nck in modulating TCR and know that it can be modulated to restore a healthy recognition of self in the body’s autoimmune system. This “reset” seems to preserve normal immune responses to antigens and turn down the volume on abnormal self-recognition. We have seen strong preclinical evidence of activity in the Th2 , Th17 , Th1/Th0 pathways, suggesting that applications could be quite broad across the autoimmune space. What will we learn from a Phase 2a Proof-of-Mechanism trial with AX-158? We will be looking for changes in a wide panel of disease-relevant biomarkers, in an effort to understand and validate the potential MoA of Nck inhibition at work clinically for the first time. There will also be clinical assessments such as PASI scores, and safety and tolerability data. We are supported by Advent Life Sciences, Columbus Ventures, Eli Lilly and Company, and Sound Bioventures, who believe in our team and the commercial and clinical potential of our Nck modulation approach. Looking ahead to first patient data later this year, we are raising a Series C round to finance the atopic dermatitis trial with lead program AX-158 and further work with AX-194, a second Nck modulator candidate. The team would be happy to walk you through the highlights of our story, to see if there could be a fit with your fund – please reach out to contact@artaxbiopharma.com to make the connection.

𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗘𝗮𝗿𝗹𝘆 𝗦𝘁𝗮𝗴𝗲 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗔𝗯𝗮𝘁𝗮 𝗧x' 𝗜𝗡𝗗 𝗳𝗼𝗿 𝗔𝗕𝗔-𝟭𝟬𝟭 𝘁𝗼 𝗯𝗲 𝘂𝘀𝗲𝗱 𝗶𝗻 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗦𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀 New treatment Abata Therapeutics announces FDA clearance for the Phase 1 clinical trial of ABA-101, an autologous TCR-Treg cell therapy designed to treat progressive multiple sclerosis (MS) by targeting CNS-compartmentalised inflammation. #MultipleSclerosis #CellTherapy Preclinical success Preclinical studies show ABA-101 is safe and effective, demonstrating tissue-specific trafficking and robust suppression of inflammation. #ClinicalTrials #Inflammation How it works: ABA-101 is an autologous Treg therapy designed for MS patients with specific HLA markers. It engineers a patient's Tregs to recognise immunogenic myelin fragments in the CNS, offering targeted anti-inflammatory effects. Read more: https://lnkd.in/eXrp8HKg Image credits: https://lnkd.in/eBskHYG3

BAMF Health is rapidly advancing cancer treatment in #GrandRapids in a partnership with Corewell Health. This two-step delivery method could potentially allow tumors to be treated with high doses of radiation, with minimal impact to other healthy organs. This trial focuses on small cell #lungcancer, #sarcoma and #melanoma in patients age 16+ #lungcancerawareness #melanomaawareness